Stockreport

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva Pharmaceuticals Holdings, Inc.  (RVPH) 
PDF CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical comp [Read more]